Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

with or without an antibiotic."

Anthim(TM) Background

Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax infection, blocking the bacteria's ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs.

About Elusys' Heteropolymer Antibody(TM) Technology

HP Antibodies represent a new approach for the treatment of antibiotic resistant infections distinct from traditional therapies. HP Antibodies utilize natural immune system mechanisms to clear pathogens and provide a means to develop novel drug candidates targeted against bacterial, viral and fungal infections. By targeting a unique immune receptor, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens from the circulation to tissue macrophages. Elusys is currently working on novel approaches to the treatment of Staphylococcus and Candida infections using HP antibodies.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... CITY, Calif., Dec. 18, 2014 Capnia, ... the development of medical diagnostics based on its ... gas flow, today announced financial results for the ... 2014. "Following the completion of our ... positioned to maximize the recently initiated CoSense® commercial ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
(Date:12/19/2014)... (PRWEB) December 19, 2014 From November 24, ... teacher training for the year 2014 in its Goa ... this year. Through the Indian winters, from November to March, ... the beautiful beach of Arambol, Goa. The Goa training sessions ... previous intakes of yoga teacher training, the 10th intake is ...
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Being in good shape seems ... They looked at data from more than 57,000 Americans, ... treadmill tests between 1991 and 2009. Those in the ... having high blood pressure at the start of the study, ... levels of fitness. Of the more than 8,000 people ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... exposed to high levels of air pollution late in pregnancy ... study suggests. Researchers found that of nearly 1,800 U.S. ... to the most air pollution during pregnancy were twice as ... exposure during the third trimester, specifically, showed the strongest correlation ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... uncertainty about risks and benefits of mastectomies or lumpectomies. ... the women diagnosed with early-stage breast cancer clearly understand ... breast-conserving lumpectomy plus radiation, even after they have one ... If the woman is black or Hispanic, the chances ...
... CNS Response,Inc. (OTC Bulletin Board: CNSO) ... roll out referenced-EEG(R) (rEEG(R)) availability with an,undisclosed, ... enables psychiatrists under the management of the ... to treat their most,therapy-challenged patients suffering any ...
... LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider of ... the opening of its 76th LasikPlus(R) vision,center in ... vision center opened this year, and the second ... a LasikPlus(R) vision,center in Paramus in April 2006., ...
... surgeons precise fingertip power control during laparoscopic procedures while, ... first in ... the healthcare industry, BOULDER, ... unique opportunity to offer surgeons greater control,and precision during surgeries ...
... 31 Ingenuity Systems, the,leading provider of ... that Path Designer, the new pathway publishing ... Best New Product by the scientific community ... San Francisco. Path,Designer enables researchers to create ...
... the United States face strikingly high levels of stigma, according ... AIDS Research. , The amfAR survey results will be ... 9 a.m. at the National Press Clubs 13th Floor First ... The press conference will be followed by a briefing in ...
Cached Medicine News:Health News:Many Women Unclear About Breast Cancer Treatments 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 3Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 4Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2Health News:Encision Moves Power and Safety to Surgeons' Fingertips 2Health News:Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference 2Health News:Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference 3Health News:Stigma clings stubbornly to women living with HIV/AIDS 2Health News:Stigma clings stubbornly to women living with HIV/AIDS 3
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Surgical Stainless Steel Child Stylette....
Surgical Stainless Steel Adult 16.5....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
Medicine Products: